▎Armstrong2025年9月5日,礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp(a)水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者,预计2031年完成。礼来于2024年11月在JAMA期刊上发表了Muvalaplin的二期临床数据。Muvalaplin治疗12周时,相比于安慰剂,...
Source Link▎Armstrong2025年9月5日,礼来在Clinicaltrials.gov网站上注册了小分子Lpa抑制剂Muvalaplin用于降低伴Lp(a)水平升高患者MACE发生风险的三期临床试验。该三期临床试验计划入组10450例Lpa升高的受试者,预计2031年完成。礼来于2024年11月在JAMA期刊上发表了Muvalaplin的二期临床数据。Muvalaplin治疗12周时,相比于安慰剂,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.